ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Effective"

  • Abstract Number: 2796 • 2017 ACR/ARHP Annual Meeting

    A Randomized, Double Blind Trial over 52 Weeks to Demonstrate Bioequivalence of GP2013 and Reference Rituximab in Patients with Rheumatoid Arthritis

    Josef S. Smolen1, Stanley B Cohen2, Morton Scheinberg3, Tamas Shisha4, Dmitrij Kollins4, Peijuan Zhu5, Liyi Cen4, Alan J. Kivitz6, Andra Rodica Balanescu7, Juan J. Gomez-Reino8 and Hans-Peter Tony9, 1Medical University Vienna, Division of Rheumatology, Department of Internal Medicine III, Vienna, Austria, 2Metroplex Clinical Research Centre, Dallas, TX, 3Rheumatology, Hospital Israelita Albert Einstein, Sao Paulo, Brazil, 4Clinical Development, Sandoz, a Novartis Division, Holzkirchen, Germany, 5Clinical Pharmacology, Sandoz, a Novartis Division, NJ, NJ, 6Altoona Center for Clinical Research, Duncansville, PA, 7Research Center of Rheumatic Diseases, “Sf. Maria” Hospital, University of Medicine and Pharmacy “Carol Davila”, Bucharest, Romania, 8BIOBADASER, Santiago, Spain, Santiago de Compostela, Spain, 9Department of Internal Medicine 2, Rheumatology and Clinical Immunology, University Hospital Würzburg, Würzburg, Germany

    Background/Purpose: Rituximab (RTX) is a mAB indicated for the treatment of RA in patients with inadequate response to anti-TNF therapy. The current study compares the…
  • Abstract Number: 449 • 2017 ACR/ARHP Annual Meeting

    Medical Bugs for Pain Relief in Patients with Rheumatoid Arthritis, a Systematic Review

    Rongqiang Zhang1, Puwei Yuan2, Jia Li3, Bo Dong1, Wulin Kang3, Stephanie Hyon4, Raveendhara R. Bannuru5, William F. Harvey4 and Chenchen Wang4, 1Shaanxi University of Chinese Medicine, Xianyang 712046, China, Xianyang, China, 2Shaanxi University of Chinese Medicine, Xianyang 712046, China, XianYang, China, 3Shaanxi University of Chinese Medicine, Xianyang, China, 4Rheumatology, Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA, 5Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA

    Background/Purpose: Medical bugs, a term used to describe insects and arthropods for medical treatment, have been widely used in the past centuries for pain relief.…
  • Abstract Number: 1205 • 2017 ACR/ARHP Annual Meeting

    Effectiveness of Low-Dose Radiation Therapy on Symptoms in Knee Osteoarthritis: First Results of a Triple Blinded, Randomized Controlled Trial

    E.A.M. Mahler1, M.J.M Minten1, M.M. Leseman-Hoogenboom2, P.M.P. Poortmans2, S.S. Boks3, J.W.J. Bijlsma4, F.H.J. van den Hoogen1,5, A.A. Den Broeder1,5 and C.H.M. van den Ende1,5, 1Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, 2Radiation Therapy, Radboud university medical centre, Nijmegen, Netherlands, 3Radiology, Sint Maartenskliniek, Nijmegen, Netherlands, 4Rheumatology and Clinical Immunology, University Medical Centre Utrecht, Utrecht, Netherlands, 5Rheumatology, Radboud university medical centre, Nijmegen, Netherlands

    Background/Purpose: Previous research in animal osteoarthritis (OA) has shown that low-dose radiation therapy (LD-RT) exerts anti-inflammatory effects, but a systematic review concluded that the evidence…
  • Abstract Number: 1464 • 2017 ACR/ARHP Annual Meeting

    Relation of HLA-DRB1 Genotype to the Efficacies of Abatacept and Tocilizumab in Patients with Rheumatoid Arthritis

    Kensuke Oryoji, The Center for Rheumatology, Matsuyama Red Cross Hospital, Ehime, Japan

    Background/Purpose: To investigate whether clinical efficacy of abatacept (ABT) and tocilizumab (TCZ) differs depending on whether or not HLA-DRB1 Shared Epitope (SE) is present in…
  • Abstract Number: 53 • 2016 ACR/ARHP Annual Meeting

    Efficacy of Cannabis Flos in Patients with Fibromyalgia: A Monocentric Observational Study

    Maria Chiara Gerardi1, Alberto Batticciotto2, Rossella Talotta1, Maria Chiara Ditto1, Fabiola Atzeni2 and Piercarlo Sarzi-Puttini1, 1Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milan, Italy, 2Rheumatology Unit, ASST Fatebenefratelli - Sacco, L. Sacco University Hospital, Milano, Italy

    Efficacy of Cannabis flos in patients with fibromyalgia: a monocentric observational study   Background/Purpose: Fibromyalgia (FM) is a syndrome characterized by chronic widespread pain, fatigue,…
  • Abstract Number: 14 • 2016 ACR/ARHP Annual Meeting

    Failure Predictors to Anti-Tumor Necrosis Antagonists in Patients with Chronic Arthritis: Results of a National Registry Biobadasar

    Maria Jezabel Haye Salinas1, Soledad Retamozo2, Alejandro Alvarellos3, Francisco Caeiro4, Juan Pablo Pirola4, Diego Baenas1, María Celina de La Vega5, Gustavo Casado6, Gimena Gomez7, Javier Roberti8, Osvaldo Luis Cerda9, Ignacio Javier Gandino10, Ana Quinteros11, Ida Exeni6,12, Juan Manuel Bande13, Juan Carlos Barreira14, Carla Gobbi15, Analia Alvarez16, Amelia Granel17, Alejandra Peluzzon18, Ana Capuccio19, Romina Nieto20, Rossana Quintana21, Eduardo Mussano22, Santiago Scarafia23, Carolina Costi24, Mercedes De La Sota25, Monica Patricia Diaz26, Edson Javier Velozo27, Santiago Aguero28, Cristina Battagliotti29, Sidney Soares de Souza30, Emilia Cavillon31, Analia Bohr32, Andrea Smichowski33, Daniela Vidal34, Dora Pereira35, Liliana Martinez36, Luis Somma37, Marta Zalazar38, Pablo Finucci Curi39, Leandro Carlevaris40, Guillermo Berbotto41 and Veronica Saurit4, 1Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, 2Rheumatology Unit, Hospital Privado Centro Médico de Córdoba, Argentina, Córdoba, Argentina, 3Rheumatology, Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, 4Rheumatology, Hospital Privado Centro Médico de Córdoba, Córdoba, Argentina, 5Sociedad Argentina de Reumatología, CABA, Argentina, 6Sociedad Argentina de Reumatologia, CABA, Argentina, 7Sociedad Argentina de Reumatología, Buenos Aires, Argentina, 8SAR, CABA, Argentina, 9IREP, CABA, Argentina, 10Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 11Centro Integral Reumatológico, Tucuman, Argentina, 12Sanatorio Parque, Cordoba, Argentina, 13Hospital Tornú, CABA, Argentina, 14Rheumatology Unit, Hospital Britanico de Buenos Aires, CABA, Argentina, 15Rheumatology, Sanatorio Allende de Córdoba, Cordoba, Argentina, 16Hospital Penna, Bahía Blanca, Argentina, 17Centro Platense de Reumatología, La Plata, Argentina, 18Hospital Clínica José de San Martín, CABA, Argentina, 19Hospital Cesar Milstein, CABA, Argentina, 20Hospital Provincial, Rosario, Argentina, 21Sanatorio Parque, Rosario, Argentina, 22Córdoba, Hospital Nacional de Clínicas, Córdoba, Argentina, 23Hospital Bernardino Rivadavia, CABA, Argentina, 24Hospital San Martín, LaPlata, Argentina, 25Consultorios, Bahia Blanca, Argentina, 26Hospital Zonal Bariloche, Bariloche, Argentina, 27Rheumatology, Sanatorio Adventista del Plata, Entre Rios, Argentina, 28Sanatorio Pasteur, Catamarca, Argentina, 29Hospital de Niños Dr Orlando Alasia, Santa Fé, Argentina, 30Ramallo 1851, REUMAR, CABA, Argentina, 31Consultorio, Cordoba, Argentina, 32Hospital de Rehabilitación Rocca, CABA, Argentina, 33Atención Integral de Reumatología, CABA, Argentina, 34Hospital de Niños de Córdoba, Córdoba, Argentina, 35Centro Raquis, Buenos Aires, Argentina, 36Hospital Fernandez, CABA, Argentina, 37SOMMA, Buenos Aires, Argentina, 38Hospital Pirovano, CABA, Argentina, 39Centro Médico Mitre, Entre Rios, Argentina, 40IARI, CABA, Argentina, 41Sanatorio Británico, Rosario, Argentina

    Background/Purpose: to analyze failure predictors to anti-tumor necrosis (TNF) therapy in patients who have switched these drugs during chronic arthritis treatment. Methods: BIOBADASAR is a…
  • Abstract Number: 244 • 2016 ACR/ARHP Annual Meeting

    Leflunomide and Glucocorticoids Combination Therapy for the Induction and Maintenance of Remission in Patients with IgG4-Related Disease

    Yiwen Wang1, Dai Gao1, Gui Luo2, Kunpeng Li1, Zheng Zhao1 and Jian Zhu1, 1Rheumatology, Chinese PLA General Hospital, Beijing, China, 2Chinese PLA General Hospital, Beijing, China

    Background/Purpose: Good response could be observed after applying glucocorticoids (GCs) in patients with IgG4-related disease (IgG4-RD), however, the risk of disease relapse was reported relatively…
  • Abstract Number: 1622 • 2016 ACR/ARHP Annual Meeting

    Safety and Efficacy of Iguratimod in Patients with Active Rheumatoid Arthritis: A Multicenter, Single-Arm, Open-Label, Real World Study

    Rong Mu, Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China

    Background/Purpose:  To evaluate the safety and efficacy of iguratimod, a novel DMARD, in active rheumatoid arthritis patients. Methods:  Patients with active rheumatoid arthritis received iguratimod…
  • Abstract Number: 2246 • 2016 ACR/ARHP Annual Meeting

    Glucocorticoids in Early Rheumatoid Arthritis Management, Friend or Foe?

    Diederik Decock1, Rene Westhovens1,2, Veerle Stouten1, Kristien Van der Elst2,3, Johan Joly2, Patrick Verschueren1,2 and CareRA Study Group, 1KU Leuven Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, Leuven, Belgium, 2Rheumatology, University Hospitals Leuven, Leuven, Belgium, 3KU Leuven, Department of Public Health and Primary Care, Skeletal Biology and Engineering Research Center, Leuven, Belgium

    Background/Purpose: ≥≥140/90 mmHg The only difference between treatments arms in either risk groups was a BMI decrease in Avant-Garde compared to Classic and Slim between baseline…
  • Abstract Number: 500 • 2015 ACR/ARHP Annual Meeting

    Ofatumumab for Rheumatoid Arthritis: A Cochrane Systematic Review and Meta-Analysis

    Vidhu Anand1, Sachit Anand2, Sushil Garg3, Maria A. Lopez-Olivo4 and Jasvinder A. Singh5, 1University of Minnesota, Minneapolis, MN, 2All India Institute of Medical Sciences, New Delhi, India, 3The University of Minnesota, Minneapolis, MN, 4General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, 5University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Ofatumumab is a unique anti-CD20 monoclonal antibody with its epitope more proximal and distinct from the epitope recognized by rituximab or by other anti-CD20…
  • Abstract Number: 713 • 2015 ACR/ARHP Annual Meeting

    Clinical and Imaging Efficacy of Etanercept in Early Non-Radiographic Axial Spondyloarthritis: 104-Week Treatment Results

    Maxime Dougados1, Désirée van der Heijde2, Joachim Sieper3, Juergen Braun4, Gustavo Citera5, Filip van Den Bosch6,7, Ronald Pedersen8, Randi Bonin9, Heather Jones10, Lisa Marshall10, Sameer Kotak11, Isabelle Logeart12, Bonnie Vlahos13, Jack F Bukowski9 and Walter Maksymowych14, 1Rheumatology Department, Hôpital Cochin, Paris, France, 2Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Medical Department I, Rheumatology, Charité Universitätesmedizin Berlin, Berlin, Germany, 4Rheumazentrum Ruhrgebiet, Herne, Germany, 5Rheumatology, Consultorios Reumatológicos Pampa, Buenos Aires, Argentina, 6Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, 7Rheumatology, Ghent University Hospital, Ghent, Belgium, 8Department of Biostatistics, Pfizer, Collegeville, PA, 9Clinical Affairs, Pfizer, Collegeville, PA, 10Inflammation Global Medical Affairs, Pfizer, Collegeville, PA, 11Global Health and Value, Pfizer, New York, NY, 12Medical Affairs, Pfizer, France, Paris, France, 13GIPB - Clinical Sciences, Pfizer, Collegeville, PA, 14Department of Medicine, University of Alberta, Edmonton, AB, Canada

    Background/Purpose: In the multiphase, randomized, placebo (PBO)-controlled EMBARK study (ClinicalTrials.gov identifier: NCT01258738), clinical signs/symptoms and MRI-measured inflammation were evaluated in patients with early, active non-radiographic…
  • Abstract Number: 750 • 2015 ACR/ARHP Annual Meeting

    Belimumab for Systemic Lupus Erythematosus: A Cochrane Systematic Review and Meta-Analysis

    Jasvinder A. Singh1 and Nipam Shah2, 1University of Alabama at Birmingham, Birmingham, AL, 2University fo Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Belimumab is a new approved treatment option for patients with lupus. Our objective was to perform a systematic review of benefits and harms of…
  • Abstract Number: 1048 • 2015 ACR/ARHP Annual Meeting

    Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor Is Effective in Combination with Methotrexate in Patients with Active Rheumatoid Arthritis: Results from a Phase 2B Dose Ranging Study

    R Westhovens1, Rieke Alten2, Dace Pavlova3, Favio Enríquez-Sosa4, Minodora Mazur5, Maria Greenwald6, Annegret Van der Aa7, Frédéric Vanhoutte7, Chantal Tasset7 and Pille Harrison7, 1Skeletal Biology and Engineering Research Center, Department of Development and Regeneration, KU Leuven, Leuven, Belgium, KU Leuven, Leuven, Belgium, 2Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, 3LTD M & M Centrs, Carnikava, Latvia, 4CLINSTILE, S.A. DE C.V, Mexico, Mexico, 5IMSP Institul de Cardiologie, Chisinau, Moldova, 6Desert Medical Advances, Palm Desert, CA, 7Galapagos NV, Mechelen, Belgium

    Background/Purpose: Filgotinib (GLPG0634) is a novel oral, potent and selective JAK1 inhibitor that has previously demonstrated efficacy in combination with methotrexate (MTX) in treating rheumatoid…
  • Abstract Number: 1049 • 2015 ACR/ARHP Annual Meeting

    Filgotinib (GLPG0634), an Oral JAK1 Selective Inhibitor Is Effective As Monotherapy in Patients with Active Rheumatoid Arthritis: Results from a Phase 2B Dose Ranging  Study

    Arthur Kavanaugh1, Lucia Ponce2, Regina Cseuz3, Olga Reshetko4, Mykola A Stanislavchuk5, Maria Greenwald6, Annegret Van der Aa7, Frédéric Vanhoutte7, Chantal Tasset7 and Pille Harrison7, 1University of California San Diego, La Jolla, CA, 2Consulta Privada Dra. Lucia Ponce, Temuco, Chile, 3Revita Reumatologiai Rendelo, Budapest, Indonesia, 4Regional Clinical Hospital, Saratov, Russia, 5Vinnitsa Regional Clinical Hospital n.a. Pirogov, Vinnitsa, Ukraine, 6Desert Medical Advances, Palm Desert, CA, 7Galapagos NV, Mechelen, Belgium

    Background/Purpose: Filgotinib (GLPG0634) is a novel oral, potent and selective JAK1 inhibitor that has previously demonstrated efficacy in combination with methotrexate (MTX) in treating rheumatoid…
  • Abstract Number: 2049 • 2015 ACR/ARHP Annual Meeting

    Long Term Effectiveness of Herpes Zoster Vaccine Among Patients with Autoimmune and Inflammatory Diseases

    Huifeng Yun1, Fenglong Xie2, John Baddley3, Kevin L. Winthrop4, Lang Chen5 and Jeffrey R. Curtis6, 1Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 2Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 3Medicine, University of Alabama at Birmingham, Birmingham, AL, 4Oregon Health and Science University, Portland, OR, 5University of Alabama at Bimingham, Birmingham, AL, 6University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: The live herpes zoster (HZ) vaccine is effective in healthy older people to reduce the incidence and burden of HZ.  Recent results from a…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology